AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001E14

Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study

Identifieur interne : 001E14 ( PascalFrancis/Corpus ); précédent : 001E13; suivant : 001E15

Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study

Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. Starkstein

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:11-0211297

Descripteurs français

Pascal (Inist)
- Trouble anxieux, Maladie de Parkinson, Angoisse anxiété, Etat dépressif, Pathologie du système nerveux, Symptomatologie, Etude transversale, Echelle d'évaluation, Inventaire.

English descriptors

KwdEn :
- Anxiety, Anxiety disorder, Cross sectional study, Depression, Evaluation scale, Inventory, Nervous system diseases, Parkinson disease, Symptomatology.

Abstract

Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study`
A11	`01`	`1`		`@1 LEENTJENS (Albert F. G.)`
A11	`02`	`1`		`@1 DUJARDIN (Kathy)`
A11	`03`	`1`		`@1 MARSH (Laura)`
A11	`04`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`05`	`1`		`@1 RICHARD (Irene H.)`
A11	`06`	`1`		`@1 STARKSTEIN (Sergio E.)`
A14	`01`			`@1 Department of Psychiatry, Maastricht University Medical Center @2 Maastricht @3 NLD @Z 1 aut.`
A14	`02`			`@1 Neurology and Movement Disorders Unit, Lille University Hospital @2 Lille @3 FRA @Z 2 aut.`
A14	`03`			`@1 Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine @2 Baltimore @3 USA @Z 3 aut.`
A14	`04`			`@1 Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health @2 Madrid @3 ESP @Z 4 aut.`
A14	`05`			`@1 Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry @2 Rochester @3 USA @Z 5 aut.`
A14	`06`			`@1 School of Psychiatry, University of Western Australia and Fremantle Hospital @2 Fremantle @3 AUS @Z 6 aut.`
A20				`@1 484-492`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000190875360170`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 11-0211297`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Trouble anxieux @5 01`
C03	`01`	`X`	`ENG`	`@0 Anxiety disorder @5 01`
C03	`01`	`X`	`SPA`	`@0 Trastorno ansiedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Angoisse anxiété @5 03`
C03	`03`	`X`	`ENG`	`@0 Anxiety @5 03`
C03	`03`	`X`	`SPA`	`@0 Angustia ansiedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Etat dépressif @5 04`
C03	`04`	`X`	`ENG`	`@0 Depression @5 04`
C03	`04`	`X`	`SPA`	`@0 Estado depresivo @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Symptomatologie @5 09`
C03	`06`	`X`	`ENG`	`@0 Symptomatology @5 09`
C03	`06`	`X`	`SPA`	`@0 Sintomatología @5 09`
C03	`07`	`X`	`FRE`	`@0 Etude transversale @5 10`
C03	`07`	`X`	`ENG`	`@0 Cross sectional study @5 10`
C03	`07`	`X`	`SPA`	`@0 Estudio transversal @5 10`
C03	`08`	`X`	`FRE`	`@0 Echelle d'évaluation @5 11`
C03	`08`	`X`	`ENG`	`@0 Evaluation scale @5 11`
C03	`08`	`X`	`SPA`	`@0 Escala evaluación @5 11`
C03	`09`	`X`	`FRE`	`@0 Inventaire @5 12`
C03	`09`	`X`	`ENG`	`@0 Inventory @5 12`
C03	`09`	`X`	`SPA`	`@0 Inventario @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Affect affectivité @5 42`
C07	`05`	`X`	`ENG`	`@0 Affect affectivity @5 42`
C07	`05`	`X`	`SPA`	`@0 Afecto afectividad @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble de l'humeur @5 43`
C07	`06`	`X`	`ENG`	`@0 Mood disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno humor @5 43`
N21				`@1 143`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0211297 INIST
ET :	Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study
AU :	LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.)
AF :	Department of Psychiatry, Maastricht University Medical Center/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore/Etats-Unis (3 aut.); Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester/Etats-Unis (5 aut.); School of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle/Australie (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 3; Pp. 484-492; Bibl. 29 ref.
LA :	Anglais
EA :	Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.
CC :	002B17; 002B17G
FD :	Trouble anxieux; Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du système nerveux; Symptomatologie; Etude transversale; Echelle d'évaluation; Inventaire
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Affect affectivité; Trouble de l'humeur
ED :	Anxiety disorder; Parkinson disease; Anxiety; Depression; Nervous system diseases; Symptomatology; Cross sectional study; Evaluation scale; Inventory
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder
SD :	Trastorno ansiedad; Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología; Sintomatología; Estudio transversal; Escala evaluación; Inventario
LO :	INIST-20953.354000190875360170
ID :	11-0211297

Links to Exploration step

Pascal:11-0211297

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0211297</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0211297 INIST</idno>
<idno type="RBID">Pascal:11-0211297</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E14</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</title>
<author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation><inist:fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation><inist:fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation><inist:fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Anxiety disorder</term>
<term>Cross sectional study</term>
<term>Depression</term>
<term>Evaluation scale</term>
<term>Inventory</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Symptomatology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble anxieux</term>
<term>Maladie de Parkinson</term>
<term>Angoisse anxiété</term>
<term>Etat dépressif</term>
<term>Pathologie du   système nerveux</term>
<term>Symptomatologie</term>
<term>Etude transversale</term>
<term>Echelle d'évaluation</term>
<term>Inventaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Medical Center</s1>
<s2>Maastricht</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>School of Psychiatry, University of Western Australia and Fremantle Hospital</s1>
<s2>Fremantle</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>484-492</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000190875360170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0211297</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trouble anxieux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Anxiety disorder</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trastorno ansiedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Depression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Symptomatologie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Symptomatology</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Sintomatología</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etude transversale</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cross sectional study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estudio transversal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Echelle d'évaluation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Evaluation scale</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Escala evaluación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Inventaire</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Inventory</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inventario</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>43</s5>
</fC07>
<fN21><s1>143</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0211297 INIST</NO>
<ET>Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study</ET>
<AU>LEENTJENS (Albert F. G.); DUJARDIN (Kathy); MARSH (Laura); MARTINEZ-MARTIN (Pablo); RICHARD (Irene H.); STARKSTEIN (Sergio E.)</AU>
<AF>Department of Psychiatry, Maastricht University Medical Center/Maastricht/Pays-Bas (1 aut.); Neurology and Movement Disorders Unit, Lille University Hospital/Lille/France (2 aut.); Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine/Baltimore/Etats-Unis (3 aut.); Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health/Madrid/Espagne (4 aut.); Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry/Rochester/Etats-Unis (5 aut.); School of Psychiatry, University of Western Australia and Fremantle Hospital/Fremantle/Australie (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 3; Pp. 484-492; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross-sectional study, 342 patients suffering from idiopathic PD underwent a research-based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty-four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono-amino oxidase (MAO)-B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Trouble anxieux; Maladie de Parkinson; Angoisse anxiété; Etat dépressif; Pathologie du   système nerveux; Symptomatologie; Etude transversale; Echelle d'évaluation; Inventaire</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Affect affectivité; Trouble de l'humeur</FG>
<ED>Anxiety disorder; Parkinson disease; Anxiety; Depression; Nervous system diseases; Symptomatology; Cross sectional study; Evaluation scale; Inventory</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Affect affectivity; Mood disorder</EG>
<SD>Trastorno ansiedad; Parkinson enfermedad; Angustia ansiedad; Estado depresivo; Sistema nervioso patología; Sintomatología; Estudio transversal; Escala evaluación; Inventario</SD>
<LO>INIST-20953.354000190875360170</LO>
<ID>11-0211297</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E14 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001E14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0211297
   |texte=   Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study

Symptomatology and Markers of Anxiety Disorders in Parkinson's Disease: A Cross-Sectional Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri